Immuneering Corp 10-Q

Item 3. Quantitative and Qualitative Disclosures about Market Risk Interest Rate Risk As of June 30, 2021, our cash and cash equivalent consists of cash held as deposits at a major financial banking institution and highly liquid investments with an original maturity of three months or less at the date of purchase. As a result, the fair value of our portfolio is relatively insensitive to interest rate changes. As of June 30, 2021, we had no variable-rate debt outstanding and are therefore not exposed to interest rate risk with respect to debt. We believe a hypothetical 100 basis point increase or decrease in interest rates during the period presented would not have had a material impact on our financial results. Foreign Currency Exchange Risk We are not currently exposed to significant market risk related to changes in foreign currency exchange rates. Our operations may be subject to fluctuations in foreign currency exchange rates in the future. Effects of Inflation We do not believe that inflation has had a material effect on our business, financial condition or results of operations. Our operations may be subject to inflation in the future .